Firazyr and Urinary tract infection - a phase IV clinical study of FDA data

Summary:

Urinary tract infection is reported as a side effect among people who take Firazyr (icatibant acetate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Sterile Water, and have Hereditary angioedema.

The phase IV clinical study analyzes which people have Urinary tract infection when taking Firazyr. It is created by eHealthMe based on reports of 5,648 people who have side effects when taking Firazyr from the FDA, and is updated regularly.

What is Firazyr?

Firazyr has active ingredients of icatibant acetate. eHealthMe is studying from 5,650 Firazyr users. Check the latest studies of Firazyr.

What is Urinary tract infection?

Urinary tract infection is found to be associated with 3,014 drugs and 3,956 conditions by eHealthMe. Check the latest studies of Urinary tract infection.

On Jul, 17, 2026

5,648 people reported to have side effects when taking Firazyr.
Among them, 79 people (1.4%) have Urinary tract infection.

Could Firazyr cause Urinary tract infection?

Among these 79 people:

How long have people been on Firazyr when they have Urinary tract infection? *

What is the gender of people who have Urinary tract infection when taking Firazyr? *

female: 93.15 %
male: 6.85 %

What is the age of people who have Urinary tract infection when taking Firazyr? *

What are other drugs people take besides Firazyr? *

What are other side effects people have besides Urinary tract infection? *

Hereditary Angioedema (recurrent episodes of severe swelling): 45 people, 56.96%
Migraine (headache): 12 people, 15.19%
Otitis (ear infection): 11 people, 13.92%
Poor Venous Access: 10 people, 12.66%
Fever: 10 people, 12.66%
Sinusitis (inflammation of sinus): 9 people, 11.39%
Stress And Anxiety: 7 people, 8.86%
Kidney Infection: 7 people, 8.86%
Fatigue (feeling of tiredness): 7 people, 8.86%
Drug Ineffective: 6 people, 7.59%

What are the existing conditions these people have? *

Hereditary Angioedema (recurrent episodes of severe swelling): 46 people, 58.23%
Immune System Disorder: 39 people, 49.37%
Nausea (feeling of having an urge to vomit): 6 people, 7.59%
Hyperemesis Gravidarum (a condition characterized by severe nausea, vomiting, weight loss, and electrolyte disturbance): 4 people, 5.06%
Immunodeficiency Common Variable: 4 people, 5.06%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 4 people, 5.06%
Dyshidrotic Eczema (skin condition in which blisters develop on the soles of your feet and/or the palms of hands): 4 people, 5.06%
Asthma: 4 people, 5.06%
Primary Immunodeficiency Syndrome: 3 people, 3.80%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 2 people, 2.53%

* Approximation only. Some reports may have incomplete information.

Do you take Firazyr and have Urinary tract infection?

- Check whether Urinary tract infection is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Firazyr:

Firazyr (5,650 reports)

Browse all side effects of Firazyr:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Urinary tract infection:

Urinary tract infection (3,014 drugs)

Browse all the conditions that are associated with Urinary tract infection:

Urinary tract infection (3,956 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on icatibant acetate (the active ingredients of Firazyr) and Firazyr (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.